PeproMene Bio
PrivateLast Round
Corporate Funding
Dec 19, 2024
Total Funding Raised
$55.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
PeproMene Bio is a clinical-stage biotechnology company that develops novel CAR T-cell therapies to treat cancers and immune disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PeproMene Bio Comparables
Compare PeproMene Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mustang Bio Inc | 75% | |
| Gilead Sciences | 73% | |
| Novartis | 72% |
PeproMene Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Dec 19, 2024 | ||||
| Series B | Jun 11, 2018 | ||||
| Series A | Sep 1, 2017 |
Key People
Founding team and executive leadership
PeproMene Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KB Investment | Series B |
| KB Investment | Series B |
| Seven Tree Equity Partners | Series B |
| Institute for Follicular Lymphoma Innovation | Corporate Funding |
| Solidus Investment | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 31% MoM.
- Nov 25, 2025
Presented BAFF-R CAR-T therapy trial results at ASH 2025.
PeproMene Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about PeproMene Bio's valuation, stock price, and market status.
Is Pepromene Bio a public or private company?
Pepromene Bio is a private company.
What is the current stock price of Pepromene Bio?
Pepromene Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Pepromene Bio worth (valuation)?
Valuation information for Pepromene Bio is not publicly available.
Can I buy Pepromene Bio stock?
Pepromene Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Pepromene Bio's last funding round?
Pepromene Bio's most recent funding round was VC Round on December 19, 2024.
Who are the main investors in Pepromene Bio?
Key investors in Pepromene Bio include Institute for Follicular Lymphoma Innovation.
Will Pepromene Bio IPO soon?
No public IPO plans have been announced for Pepromene Bio.
How can I track Pepromene Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pepromene Bio's secondary market activity and sign up for updates.